These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30855016)

  • 1. The future of molecular and functional imaging in prostate cancer.
    Renard-Penna R; Gauthé M
    Arch Esp Urol; 2019 Mar; 72(2):150-156. PubMed ID: 30855016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
    Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
    Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography (PET) radiotracers for prostate cancer imaging.
    Walker SM; Lim I; Lindenberg L; Mena E; Choyke PL; Turkbey B
    Abdom Radiol (NY); 2020 Jul; 45(7):2165-2175. PubMed ID: 32047993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
    Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
    Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging in prostate cancer staging: present role and future perspectives.
    Pinto F; Totaro A; Palermo G; Calarco A; Sacco E; D'Addessi A; Racioppi M; Valentini A; Gui B; Bassi P
    Urol Int; 2012; 88(2):125-36. PubMed ID: 22286304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging.
    Bouchelouche K; Turkbey B; Choyke P; Capala J
    Curr Urol Rep; 2010 May; 11(3):180-90. PubMed ID: 20425625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of distant metastases of prostate cancer.
    Pesapane F; Czarniecki M; Suter MB; Turkbey B; Villeirs G
    Med Oncol; 2018 Sep; 35(11):148. PubMed ID: 30218382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer].
    Mirzaei S; Knoll P; Zandieh S
    Wien Med Wochenschr; 2019 Feb; 169(1-2):12-14. PubMed ID: 30349972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
    Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A
    Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostate cancer imaging: MRI and nuclear imaging].
    Renard Penna R; Brenot-Rossi I; Salomon L; Soulié M
    Prog Urol; 2015 Nov; 25(15):933-46. PubMed ID: 26519961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
    McEwan LM; Wong D; Yaxley J
    J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
    Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S
    Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
    Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
    J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
    Mottaghy FM; Heinzel A; Verburg FA
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1397-9. PubMed ID: 27118189
    [No Abstract]   [Full Text] [Related]  

  • 18. The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.
    Sathianathen NJ; Geurts N; Nair R; Lawrentschuk N; Murphy DG; Lamb AD
    Future Oncol; 2017 Aug; 13(20):1801-1807. PubMed ID: 28762288
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
    AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
    Gorin MA; Rowe SP; Denmeade SR
    PET Clin; 2017 Apr; 12(2):185-192. PubMed ID: 28267452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.